Scott A. McMurry

Federal Circuit Invalidates Patent Term Adjustments For Obviousness-Type Double Patenting

Does PTAB's Ex Parte Cellect Decision Endanger Biopharmaceutical Patent Terms?

Does The PTAB's Recent Ex Parte Cellect Decision Signal Concern For The Valuable Patent Terms Of Biopharmaceuticals?

Asia IP & TMT: Quarterly Review - Second Quarter 2019